What are the indications for Levetiracetam, Aripiprazole, Phenytoin, and Divalproex (Valproate) in seizure disorder management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Levetiracetam, phenytoin, and divalproex (valproate) are indicated for the management of seizure disorders, including status epilepticus, while aripiprazole is not primarily an antiepileptic but may be used adjunctively for psychiatric comorbidities in epilepsy patients. The indications for these medications are based on their efficacy in controlling seizures and improving patient outcomes, as supported by recent studies 1.

Medication Overview

  • Levetiracetam is a broad-spectrum antiepileptic drug effective for partial-onset, myoclonic, and generalized tonic-clonic seizures, typically started at 500mg twice daily and titrated up to 1500-3000mg daily in divided doses.
  • Phenytoin is primarily used for generalized tonic-clonic seizures and status epilepticus, with loading doses of 15-20mg/kg followed by maintenance of 300-400mg daily, requiring therapeutic drug monitoring due to its narrow therapeutic index.
  • Divalproex is effective for multiple seizure types including absence, myoclonic, and generalized tonic-clonic seizures, usually started at 10-15mg/kg/day and titrated to 20-60mg/kg/day with target blood levels of 50-100 μg/mL.
  • Aripiprazole is not primarily an antiepileptic but may be used adjunctively for psychiatric comorbidities in epilepsy patients, acting on dopamine and serotonin receptors.

Treatment Selection

Treatment selection should consider seizure type, patient comorbidities, potential drug interactions, and side effect profiles, with regular monitoring for efficacy and adverse effects, as recommended by recent guidelines 1. The use of these medications should be guided by the most recent and highest quality evidence, prioritizing patient outcomes and minimizing potential harms.

Key Considerations

  • The benefit of early treatment and cessation of status epilepticus is a reduction in morbidity and mortality, as highlighted in a recent study 1.
  • The potential for adverse drug reactions should be carefully considered, with monitoring for side effects such as nausea, rash, and liver toxicity.
  • Regular monitoring of therapeutic drug levels and adjustment of doses as needed is crucial to optimize treatment efficacy and minimize adverse effects.

From the FDA Drug Label

Levetiracetam is indicated as adjunctive treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy Levetiracetam is indicated as adjunctive therapy in the treatment of primary generalized tonicoclonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. Phenytoin is indicated for the control of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.

The indications for Levetiracetam are:

  • Adjunctive treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.
  • Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.
  • Adjunctive therapy in the treatment of primary generalized tonicoclonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. The indications for Phenytoin are:
  • Control of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures.
  • Prevention and treatment of seizures occurring during or following neurosurgery. There is no information about Aripiprazole and Divalproex in the provided drug labels, therefore their indications cannot be determined from this information 2, 3.

From the Research

Indications for Levetiracetam

  • Levetiracetam is approved as an adjunctive therapy in the treatment of partial and generalized tonic-clonic seizures in children and adults with epilepsy 4.
  • It is used for seizure prophylaxis in patients presenting with subarachnoid hemorrhage (SAH) or traumatic brain injury (TBI) 5.
  • Levetiracetam may provide mood-stabilizing qualities through a mechanism that is unique from that of other antiepileptic agents used for their mood-stabilizing properties 6.
  • It is effective and well-tolerated as an adjunctive treatment for patients with previously uncontrolled idiopathic generalized epilepsy with myoclonic seizures 7.

Indications for Aripiprazole

  • There is no direct evidence in the provided studies for the indications of Aripiprazole in seizure disorder management.

Indications for Phenytoin

  • Phenytoin is used as a monotherapy in newly diagnosed generalized epilepsy (tonic clonic type) 8.
  • It is also used as an alternative treatment option for patients with drug-resistant generalized epilepsy 8.

Indications for Divalproex (Valproate)

  • Divalproex is used as a monotherapy in newly diagnosed generalized epilepsy (tonic clonic type) 8.
  • It is also used as an alternative treatment option for patients with drug-resistant generalized epilepsy 8.
  • Divalproex may cause adverse events such as hyperammonemia 6.

Related Questions

What are the recommendations for managing the interaction between levetiracetam (Keppra) and sertraline (Zoloft) in patients with seizure disorders and depression?
What is the recommended treatment approach for patients with seizures and mood disorders using Keppra (levetiracetam)?
What medication should be prescribed for a 27-year-old woman with depression, seizure disorder, and obesity, currently taking Keppra (levetiracetam), with a Patient Health Questionnaire-9 (PHQ-9) score indicating moderate to severe depression?
How to taper off Keppra (levetiracetam) in a patient likely without a seizure disorder?
What is the best course of action for a patient with schizophrenia, major depressive disorder (MDD), and anxiety, who is taking Keppra (levetiracetam) 500 mg orally twice a day and Topamax (topiramate) 50 mg orally twice a day, when primary care claims she has no history of seizure disorder and the past medical history is unclear?
What is the typical treatment for sinusitis?
Is alprazolam (Xanax) effective for treating myoclonus?
What is the recommended warming protocol for patients undergoing Targeted Temperature Management (TTM) after cardiac arrest?
What is the management approach for a patient with low Mean Corpuscular Hemoglobin (MCH) but a normal Complete Blood Count (CBC)?
Is 40mg of omprazole (proton pump inhibitor) every 12 hours as effective as continuous infusion in managing upper gastrointestinal bleeding, and does omprazole reduce mortality, while also considering the role of tranexamic acid in upper and lower gastrointestinal bleeding?
What is the treatment for gallbladder sludge?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.